QIAGEN Launches QIAcube Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
March 02 2021 - 4:11PM
Business Wire
- QIAcube Connect MDx carries CE-IVD marking in Europe and will
be launched globally
- Device allows labs to use in-vitro diagnostics (IVD) and more
than 140 other QIAGEN standard protocols
- Platform builds on success of over 9,800 installed QIAcube and
QIAcube Connect instruments
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced the global launch of the QIAcube Connect MDx, a flexible
platform for automated sample processing that will now be available
to molecular diagnostic laboratories in the U.S. and Canada, the
European Union and other markets worldwide.
QIAcube Connect MDx is an enhanced instrument from the QIAcube
product line for in-vitro diagnostic applications (IVD) that tests
samples taken from the human body. The fully automated, flexible
system with diagnostic and research protocols can be used in
combination with QIAGEN’s gold standard QIAamp DSP kits and PAXgene
Blood RNA extraction kits.
This expansion to clinical applications complements the use of
QIAcube Connect and the QIAcube HT instruments in life science
applications. QIAGEN has placed more than 9,800 instruments of the
QIAcube instrument family by the end of 2020. It also further
enhances QIAGEN’s automated sample preparation portfolio led by the
QIAsymphony flagship system.
The new QIAcube Connect MDx version is compliant with medical
device design standards and regulations and increases lab-process
safety with a complete IVD system, which can also be used to
prepare SARS-CoV-2 and other viral samples for diagnostic testing.
The platform can be used with over 80 QIAGEN kits and more than 140
standard protocols and ensures full standardization of the
purification of multiple sample types.
Researchers can be freed up from repetitive and costly manual
processing by allowing laboratories to automate the first steps of
molecular diagnostic workflows through the use of QIAGEN’s
gold-standard spin column technologies for DNA, RNA and protein
sample processing.
Please find the full press release here.
For more information about QIAcube Connect MDx platform, please
visit our product page. Further information on QIAGEN’s response to
the coronavirus outbreak can be found here.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210302006110/en/
QIAGEN Investor Relations John Gilardi, +49 2103
29 11711 Phoebe Loh, +49 2103 29 11457 e-mail: ir@QIAGEN.com
Public Relations Thomas Theuringer, +49 2103 29 11826
Robert Reitze, +49 2103 29 11676 e-mail: pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024